Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
Lobo SM, Plantefève G, Nair G, Joaquim Cavalcante A, Franzin de Moraes N, Nunes E, Barnum O, Berdun Stadnik CM, Lima MP, Lins M, Hajjar LA, Lipinski C, Islam S, Ramos F, Simon T, Martinot JB, Guimard T, Desclaux A, Lioger B, Neuenschwander FC, DeSouza Paolino B, Amin A, Acosta SA, Dilling DF, Cartagena E, Snyder B, Devaud E, Barreto Berselli Marinho AK, Tanni S, Milhomem Beato PM, De Wit S, Selvan V, Gray J, Fernandez R, Pourcher V, Maddox L, Kay R, Azbekyan A, Chabane M, Tourette C, Esmeraldino LE, Dilda PJ, Lafont R, Mariani J, Camelo S, Rabut S, Agus S, Veillet S, Dioh W, van Maanen R, Morelot-Panzini C. Lobo SM, et al. Among authors: desclaux a. EClinicalMedicine. 2024 Jan 3;68:102383. doi: 10.1016/j.eclinm.2023.102383. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38545090 Free PMC article.
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).
Carvelli J, Meziani F, Dellamonica J, Cordier PY, Allardet-Servent J, Fraisse M, Velly L, Barbar SD, Lehingue S, Guervilly C, Desgrouas M, Camou F, Piperoglou C, Vely F, Demaria O, Karakunnel J, Fares J, Batista L, Rotolo F, Viotti J, Boyer-Chammard A, Lacombe K, Le Dault E, Carles M, Schleinitz N, Vivier E; FOR COVID Elimination (FORCE) Study Group. Carvelli J, et al. Crit Care Med. 2022 Dec 1;50(12):1788-1798. doi: 10.1097/CCM.0000000000005683. Epub 2022 Oct 10. Crit Care Med. 2022. PMID: 36218354 Free PMC article. Clinical Trial.
Severe Bacterial Non-AIDS Infections in Persons With Human Immunodeficiency Virus: The Epidemiology and Evolution of Antibiotic Resistance Over an 18-Year Period (2000-2017) in the ANRS CO3 AquiVih-Nouvelle-Aquitaine Cohort.
Blanc P, Bonnet F, Leleux O, Perrier A, Bessede E, Pereyre S, Cazanave C, Neau D, Vareil MO, Lazaro E, Duffau P, Saunier A, André K, Wittkop L, Vandenhende MA; ANRS CO3 AquiVih-Nouvelle-Aquitaine Cohort Study Group. Blanc P, et al. Clin Infect Dis. 2023 May 24;76(10):1814-1821. doi: 10.1093/cid/ciac978. Clin Infect Dis. 2023. PMID: 36610063
Covichem: A biochemical severity risk score of COVID-19 upon hospital admission.
Bats ML, Rucheton B, Fleur T, Orieux A, Chemin C, Rubin S, Colombies B, Desclaux A, Rivoisy C, Mériglier E, Rivière E, Boyer A, Gruson D, Pellegrin I, Trimoulet P, Garrigue I, Alkouri R, Dupin C, Moreau-Gaudry F, Bedel A, Dabernat S. Bats ML, et al. Among authors: desclaux a. PLoS One. 2021 May 6;16(5):e0250956. doi: 10.1371/journal.pone.0250956. eCollection 2021. PLoS One. 2021. PMID: 33956870 Free PMC article.
Time to Treatment Initiation and HIV Viral Suppression in People Diagnosed With HIV-1 During COVID-19 Pandemic in Ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study).
Ben Farhat J, Hessamfar M, Farbos S, Desclaux A, Dumondin G, Ferrand H, Greib C, Castan B, Rispal P, Duffau P, Leleux O, Perrier A, Wittkop L, Bonnet F, Barger D. Ben Farhat J, et al. Among authors: desclaux a. J Acquir Immune Defic Syndr. 2024 Jan 1;95(1):1-5. doi: 10.1097/QAI.0000000000003310. J Acquir Immune Defic Syndr. 2024. PMID: 37757852
140 results